Equities Analysts Set Expectations for TRDA Q2 Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – HC Wainwright issued their Q2 2026 earnings per share estimates for Entrada Therapeutics in a research note issued on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($1.12) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.42) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.36. The firm had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.

Entrada Therapeutics Stock Performance

Shares of TRDA stock opened at $7.69 on Wednesday. Entrada Therapeutics has a one year low of $7.10 and a one year high of $21.79. The firm’s 50 day moving average price is $8.76 and its 200-day moving average price is $13.26. The firm has a market cap of $291.86 million, a P/E ratio of 4.84 and a beta of 0.04.

Institutional Trading of Entrada Therapeutics

A number of large investors have recently modified their holdings of TRDA. KLP Kapitalforvaltning AS purchased a new stake in shares of Entrada Therapeutics in the 4th quarter valued at approximately $36,000. BNP Paribas Financial Markets acquired a new position in Entrada Therapeutics in the fourth quarter valued at approximately $57,000. Virtus ETF Advisers LLC purchased a new stake in shares of Entrada Therapeutics during the 4th quarter worth approximately $68,000. AlphaQuest LLC purchased a new stake in Entrada Therapeutics in the fourth quarter valued at $70,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of Entrada Therapeutics by 53,455.6% during the fourth quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company’s stock worth $83,000 after purchasing an additional 4,811 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.